Nordson Co. (NASDAQ:NDSN) experienced
mixed performance recently, with shares
purchased by Natixis, Bessemer Group Inc., Twin Capital Management Inc., and Vanguard Group Inc., among others. However, the company reported a
lower profit and
flat sales for Q2, followed by
trimming its sales and earnings guidance. Allegations of potential weakness were indicated as
insiders sold US$1.2m in stock. On a strategic part, Nordson plans to
bolster its medical portfolio through an $800 million acquisition of Atrion Corporation, further expanding into medical infusion and cardiovascular technologies. Institutional shareholders who own 73% of the company substantially
control Nordson. Nordson seems to use its
debt quite sensibly, changes in the executive body included
appointment of Daniel Hopgood as Chief Financial Officer. Analysts noted that Nordson stock, despite a recent fall, is undervalued as a
Dividend Aristocrat. The company's
diversification effort is reflect in acquiring ARAG, NDC Technologies and CyberOptics Corporation, expanding test, inspection, and dispense capabilities. Nordson has also completed broad-scale business realignment focused on
profitable growth.
Nordson Corp NDSN News Analytics from Tue, 22 May 2012 07:00:00 GMT to Sun, 28 Jul 2024 14:49:44 GMT -
Rating -2
- Innovation 4
- Information 6
- Rumor 2
